Get the Stockscreener App
76.74
1.03%
0.78
Ptc Therapeutics Inc stock is traded at $76.74, with a volume of 768.33K.
It is up +1.03% in the last 24 hours and down -2.24% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$75.96
Open:
$76.35
24h Volume:
768.33K
Relative Volume:
0.53
Market Cap:
$6.16B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-12.92
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
-2.32%
1M Performance:
-2.24%
6M Performance:
+56.13%
1Y Performance:
+67.26%
1-Day Range:
$75.02
$76.75
1-Week Range:
$75.02
$78.67
52-Week Range:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
76.74 | 6.10B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Matthew Klein Sells 8,089 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Behavioral Patterns of PTCT and Institutional Flows - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest - TipRanks
PTC Therapeutics Signs Royalty Purchase Agreement Amendment With Royalty Pharma - TradingView — Track All Markets
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - AOL.com
Pacer Advisors Inc. Has $30.93 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
PTC Therapeutics Earnings Notes - Trefis
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 20,508 Shares of Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over 20,000 Shares - TradingView — Track All Markets
Director Reeve Emma exercised 733 shares at a strike of $46.54 and sold $57,628 worth of shares (733 units at $78.62) (SEC Form 4) - Quantisnow
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - Sahm
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics’ (PTCT) Rare-Disease Strategy - Yahoo Finance
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch - Yahoo Finance
(PTCT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) - GuruFocus
PTC Therapeutics' Phenylketonuria Treatment Approved in Japan - marketscreener.com
PTC Therapeutics receives Japan approval for PKU treatment Sephience By Investing.com - Investing.com Nigeria
Voya Investment Management LLC Has $17.48 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Gains Japanese Approval for Phenylketonuria Treatment - GuruFocus
PTC Therapeutics receives Japan approval for PKU treatment Sephience - Investing.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
Assessing PTC Therapeutics (PTCT) Valuation After Health Canada’s Sephience Approval Expands PKU Market Potential - Sahm
EPS Watch: Why millennials buy PTC Therapeutics Inc. (BH3) stock2025 Winners & Losers & Short-Term Swing Trade Alerts - ulpravda.ru
PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo - The Globe and Mail
Will PTC Therapeutics Inc. stock attract more institutional investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - Улправда
Insider Sell Alert: Eric Pauwels Sells 43,492 Shares of PTC Ther - GuruFocus
Eric Pauwels Sells 3,202 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over $3 Million in Company Stock - TradingView — Track All Markets
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Officer Pauwels Files To Sell 20,508 Of PTC Therapeutics Inc [PTCT] - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Is PTC Therapeutics Inc. (BH3) stock undervalued by metricsQuarterly Portfolio Report & Free Reliable Trade Execution Plans - Улправда
Why PTC Therapeutics Inc. stock remains resilient2025 Price Momentum & Daily Volume Surge Trade Alerts - DonanımHaber
Is PTC Therapeutics Inc. stock a defensive play in 2025Market Performance Summary & Low Drawdown Momentum Ideas - DonanımHaber
Aug Catalysts: Is PTC Therapeutics Inc. (BH3) stock undervalued by metrics2025 Investor Takeaways & Real-Time Volume Spike Alerts - ulpravda.ru
PTC Therapeutics (PTCT) director exercises stock option, now holds 155,266 shares - Stock Titan
Why hedge funds are buying PTC Therapeutics Inc. stockJuly 2025 Technicals & Fast Entry and Exit Trade Plans - Улправда
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healt - GuruFocus
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nasdaq
Officer Pauwels Files To Sell 40,290 Of PTC Therapeutics Inc [PTCT] - TradingView — Track All Markets
PTC Therapeutics (PTCT) Is Down 9.5% After Broad S&P Additions And Insider Moves Has The Bull Case Changed? - Sahm
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Quantisnow
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript - MSN
Squarepoint Ops LLC Grows Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):